Abstract
Haemonchus contortus, one of the most economically important parasites of small ruminants, has become resistant to the anthelmintic ivermectin. Deciphering the role of P-glycoproteins in ivermectin resistance is desirable for understanding and overcoming this resistance. In the model nematode, Caenorhabditis elegans, P-glycoprotein-13 is expressed in the amphids, important neuronal structures for ivermectin activity. We have focused on its ortholog in the parasite, Hco-Pgp-13. A 3D model of Hco-Pgp-13, presenting an open inward-facing conformation, has been constructed by homology with the Cel-Pgp-1 crystal structure. In silico docking calculations predicted high affinity binding of ivermectin and actinomycin D to the inner chamber of the protein. Following in vitro expression, we showed that ivermectin and actinomycin D modulated Hco-Pgp-13 ATPase activity with high affinity. Finally, we found in vivo Hco-Pgp-13 localization in epithelial, pharyngeal and neuronal tissues. Taken together, these data suggest a role for Hco-Pgp-13 in ivermectin transport, which could contribute to anthelmintic resistance.
Keywords: Nematode, Haemonchus contortus, ABC transporters, P-glycoprotein, Ivermectin, Homology modeling
Abbreviations: ABC, ATP-binding cassette; ACD, actinomycin D; AH, anthelmintic; BlastP, protein Basic Local Alignment Search Tool; bp, base pairs; Cel, Caenorhabditis elegans; Hco, Haemonchus contortus; Hsa, Homo sapiens; IVM, ivermectin; MDR, multidrug resistance; ML, macrocyclic lactone(s); Mmu, Mus musculus; NBD, nucleotide binding domain; PDB, Protein data bank; Pgp, P-glycoprotein; QMEAN, Qualitative Model Energy Analysis; RMSD, root mean square deviation; SNP, single nucleotide polymorphism; TM(D), transmembrane (domain)
Graphical abstract
Highlights
-
•
H. contortus Hco-Pgp-13 is ortholog of C. elegans Cel-Pgp-12, Cel-Pgp-13, Cel-Pgp-14.
-
•
Hco-Pgp-13 was modeled by homology with the Cel-Pgp-1 crystal structure.
-
•
In silico docking showed high affinity of ivermectin and actinomycin D to Hco-Pgp-13.
-
•
Ivermectin and actinomycin D modulated Hco-Pgp-13 ATPase activity with high affinity.
-
•
Hco-Pgp-13 localization to H. contortus epithelial, pharyngeal and neuronal tissues.
1. Introduction
Parasite nematodes cause morbidity in animals and humans and macrocyclic lactones (ML), such as ivermectin (IVM), are important anthelmintic drugs for therapy (Campbell, 2016, Ōmura, 2016). However, the long-term use of ML has led to the development of drug resistance, challenging therapeutic control (Kaplan and Vidyashankar, 2012).
The multi-drug resistance (MDR) transporters from the ATP-binding cassette (ABC) protein superfamily are involved in the transport of structurally unrelated xenotoxins, and have been recognized as major players in resistance to drugs in mammals, bacteria and parasites (Lage, 2003, Jones and George, 2005, Koenderink et al., 2010). In mammals, P-glycoprotein (MDR1/ABCB1/Pgp) can efflux structurally unrelated drugs, including IVM (Schinkel et al., 1994, Pouliot et al., 1997, Roulet et al., 2003, Lespine et al., 2007). Many Pgps, i.e. full-size transporters of the B sub-family, are expressed in nematodes, and they display fair sequence homologies with human ABCB1. The free-living nematode Caenorhabditis elegans expresses sixty ABC proteins, among which fourteen Pgp homologs are localized in different organs and expressed at various stages of development (Zhao et al., 2004). Haemonchus contortus, one of the most prevalent pathogen parasitic nematodes in small ruminants, is genetically close to Caenorhabditis elegans and its genome has recently been sequenced (Laing et al., 2013) (ftp://ftp.sanger.ac.uk/pub/pathogens/Haemonchus/contortus). In this species, ten homologs of Pgps were identified, and two have been localized: Hco-Pgp-2 in the pharynx, anterior intestine and head neurons, and Hco-Pgp-9.1 in the uterus of females (Godoy et al., 2015a, Godoy et al., 2016).
There is indirect but converging evidence that some nematode Pgps can transport ML, in C. elegans (Ardelli and Prichard, 2013, Janssen et al., 2013a, Janssen et al., 2015) and in Parascaris equorum (Janssen et al., 2013b). Some mammalian Pgp inhibitors alter the transport function of Pgps in C. elegans and in the parasitic nematodes H. contortus, Cylicocylus elongatus and Dirofilaria immitis (Kaschny et al., 2015, Godoy et al., 2015a, Godoy et al., 2015b, Godoy et al., 2016, Mani et al., 2016). Such inhibitors can also improve the susceptibility of nematodes to ML (Bartley et al., 2009, James and Davey, 2009, Lespine et al., 2012, Menez et al., 2016). In addition, increased ML resistance is associated with induction of expression of Pgp genes (James and Davey, 2009, Lespine et al., 2012). Recently, using the first crystal structure of a nematode Pgp, Cel-Pgp-1, resolved at a resolution of 3.4 Å (Protein Data Bank code: 4F4C) (Jin et al., 2012), high affinity binding of several anthelmintic drugs, including IVM, on Cel-Pgp-1 has been predicted by in silico docking calculations (David et al., 2016).
To understand the respective physiological functions of Pgps in H. contortus, it is of interest to consider their sites of expression. In both C. elegans and H. contortus, IVM resistance has been linked to defects in the morphology of the amphids (Freeman et al., 2003, Urdaneta-Marquez et al., 2014, Menez et al., 2016). Cel-Pgp-6 and Cel-Pgp-13 are expressed in the amphids (Zhao et al., 2004). H. contortus does not have a homolog of Cel-Pgp-6, but it has a homolog of Cel-Pgp-13, and it was therefore of interest to characterize Hco-Pgp-13. Full-length Hco-Pgp-13 cDNA was cloned and transfected into Pichia pastoris which stably expressed functional Hco-Pgp-13. Based on the crystal structure 4F4C of Cel-Pgp-1 (Jin et al., 2012), the protein was 3D modeled in open inward-facing conformation, which is expected to be competent for substrate uptake, leading to two high-quality, alternative but complementary, structural models. Using in silico docking on these models, in combination with in vitro ATPase assays on membranes of Hco-Pgp-13 transfected P. pastoris, we show for the first time that actinomycin D (ACD) and IVM specifically bind to Hco-Pgp-13 and modulate its ATPase activity, and could hence be transported by the parasitic Hco-Pgp-13. Furthermore, the expression of Hco-Pgp-13 in the tissues of H. contortus larvae and adults was assessed. Our finding of apparent Hco-Pgp-13 expression in digestive, epithelial and neuronal tissues is consistent with a general detoxification function, possibly handling various xenobiotics, in analogy with ABCB1 in mammals. Finally, in the context of anthelmintic drug resistance in parasitic nematodes, Hco-Pgp13 is likely to have a role in IVM resistance.
2. Material and methods
2.1. Parasites
The PF23 strain of H. contortus used is susceptible to MLs (Ranjan et al., 2002). Worms were originally supplied by Fort Dodge Animal Health, Princeton, NJ, USA and were maintained by our laboratory. Animals and standardized operating procedures used in this research study were approved (Protocol 3845) and subjected to the guidelines from the Animal Care Committee of McGill University, Canada. Worms were obtained from passages consisting of an artificial infection with the larvae from the previous generation in naive lambs, without anthelmintic exposure. They were then collected from the abomasum of the host and incubated in PBS at 37 °C before storage at -80 °C.
2.2. RNA extraction and reverse transcription
Total RNA was extracted from twenty adult H. contortus, homogenized and extracted according to the instruction of the manufacturer (ThermoFisher, Canada). RNA concentration was determined with a Nanodrop photometer IMPLEN® at a wavelength of 260 nm and assessed by gel electrophoresis. Good quality RNA was stored at -80 °C. The reverse transcription to cDNA was performed using the SuperScript® III reverse transcriptase (ThermoFisher, Canada), starting with 1 μg RNA and following the instructions of the manufacturer. The cDNA obtained was stored at -20 °C for further use.
2.3. Amplification of the Hco-Pgp-13 cDNA sequence
A pair of primers, Hco-Pgp-13-F1 and Hco-Pgp-13-R2 (Suppl. Table S1), were designed using the Geneious software version 5.5.6. (http://www.geneious.com/; PO Box 5677, Wellesley St, Auckland 1141, New Zealand), across the 3’ end of the predicted sequence of Hco-Pgp-13 from the Sanger Institute (ftp://ftp.sanger.ac.uk/pub/pathogens/Haemonchus/contortus) (Laing et al., 2013). A first PCR was run using these primers and the reverse transcribed cDNA of whole adult H. contortus as template. A fragment of 3488bp was obtained and sequenced (Genome Quebec Innovation Centre, McGill University, QC, Canada) using eight primers, Hco-Pgp-13-F1 to Hco-Pgp-13-R8 (Supplementary Table S1).
Four more primers were designed to identify the 5′-end of Hco-Pgp-13 by nested PCR: the nematode spliced leader sequence SL1 (Blaxter and Liu, 1996), a specific forward primer Hco-Pgp-13–F9 (Supplementary Table S1) and two specific reverse primers Hco-Pgp-13–R10 and Hco-Pgp-13-R11 (Supplementary Table S1). The 887 bp PCR products thus obtained were sequenced and aligned to the first 3488 bp product with MultAlin software (Corpet, 1988), and the overlap of the amplicons confirmed. The full-length sequence was then aligned against the cDNA of the predicted sequence of Hco-Pgp-13 using MultAlin (Supplementary Figure S1).
2.4. Determination of Hco-Pgp-13 protein sequence, phylogenic analysis and calculation of TMD homologies relative to Cel-Pgp-1
The translation of Hco-Pgp-13 cDNA into protein sequence was performed using ExPASy – Translate tool (http://web.expasy.org/translate/). The parameters of the protein (molecular weight, length) were calculated with ExPASy – ProtParam (http://web.expasy.org./protparam/). The presence of N- and O-glycosylation motifs was predicted using ExPASy - ScanProsite tool (http://prosite. Expasy. org/), as well as that of consensus motifs, including the Walker A and the less conserved Walker B motif. Multiple sequence alignment of Pgps of various organisms, including Hsa-Pgp (Supplementary Figure S2), was performed using Muscle algorithm under Seaview software (Edgar, 2004a, Edgar, 2004b). The prediction of amino acids located within the transmembrane bilayer was performed with the Protter tool (Omasits et al., 2014) and the TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/). The visualization of the topology of the full length protein sequence across the plasma membrane was represented using the Protter tool (Fig. 1). The TM helices and eight N-glycosylation motifs were represented as predicted by this program, N518 being the only one not previously predicted by ExPASy - ScanProsite.
A PhyML phylogenetic tree with all Hco-Pgps, all Cel-Pgps, Hsa-Pgp and Mmu-ABCB1a protein sequences (Fig. 2) was constructed using Seaview software from the multiple alignments previously performed with Muscle (Supplementary Figure S2) after removal of NBDs from all the considered protein sequences.
The locations of the TMDs of all the proteins of this alignment were deduced from Cel-Pgp-1 4F4C crystal structure (Jin et al., 2012). The first amino acid of TMD1 of each Pgp was identified as the one aligned to the first amino-acid of TM1 of Cel-Pgp-1, thus excluding the small extra-helix TMa and TMb (Jin et al., 2012) not previously described in other ABC transporters, and considered to be part of the N-terminal region. The similarity and identity percentages of the TMDs of Cel-Pgp-1 with the TMDs of all other Pgps were then determined using BlastP (http://blast.ncbi.nlm. nih. gov/Blast.cgi). TMD1 and TMD2 were considered independently, and the mean of the two values for each Pgp is reported in Table 1.
Table 1.
Cel-Pgp-1 | % Identity | % Similarity |
---|---|---|
Hco-Pgp-1 | 63 | 79 |
Hco-Pgp-9.1 | 50 | 69 |
Cel-Pgp-9 | 48 | 67 |
Hsa-Pgp | 36 | 58 |
Cel-Pgp-2 | 35 | 57 |
Mmu-Abcb1a | 35 | 56 |
Hco-Pgp-2 | 34 | 56 |
Hco-Pgp-13 | 33 | 54 |
Hco-Pgp-16 | 32 | 52 |
Cel-Pgp-3 | 30 | 52 |
Hco-Pgp-3 | 31 | 51 |
Cel-Pgp-4 | 30 | 51 |
Cel-Pgp-8 | 29 | 51 |
Cel-Pgp-12 | 28 | 51 |
Hco-Pgp-17 | 25 | 51 |
Cel-Pgp-5 | 30 | 50 |
Cel-Pgp-14 | 29 | 50 |
Cel-Pgp-13 | 27 | 50 |
Cel-Pgp-7 | 29 | 49 |
Cel-Pgp-6a | 29 | 49 |
Hco-Pgp-11 | 25 | 46 |
Cel-Pgp-11 | 22 | 45 |
Hco-Pgp-10 | 22 | 42 |
Cel-Pgp-10 | ND | ND |
2.5. Design of specific antibodies against Hco-Pgp-13
The specificity and suitability of various antigens for antibody production against Hco-Pgp-13 were analyzed by GenScript. Among several potential antigenic determinants identified, two peptides were chosen for their disordered structure and high accessibility in the predicted 3D conformation of the protein: GTADPQRSSETSKK (residues 12-25) and SGRSTLTQSKRSGS (residues 681-694). They were chemically synthesized and used to immunize rabbits (GenScript, USA). The polyclonal antibodies generated were assessed in Western blots.
2.6. Expression of Hco-Pgp-13
The full-length cDNA sequence of Hco-Pgp-13 was subjected to codon optimization by GenScript (NJ, USA). After transformation of the vector in Escherichia coli TOP10F’ competent cells, Hco-Pgp-13 codon optimized sequence was confirmed by sequencing (Genome Quebec Innovation Centre, McGill University, QC, Canada). Expression of codon optimized Hco-Pgp-13 was undertaken in both epithelial pig kidney cells (LLC-PK1) and P. pastoris. Membrane fractions extracted from Hco-Pgp-2/LLC-PK1 transfected cells (Godoy et al., 2015a) and from Hco-Pgp-13/LLC-PK1 were prepared as previously described (Garrigues et al., 2002).
For expression in P. pastoris, Hco-Pgp-13 coding sequence was modified at the 5′ end and the 3′ end by introducing BstBI and XbaI sites, respectively, by PCR amplification with the following primers: BstBI-Hco-Pgp-13: 5′AAAACAACTTAATTATTATTCGAAACGATGACATCAAAACCCGAT′3 (forward) and XbaI-Hco-Pgp-13: 5′TAGCTAGCTAGCTAGCTAGTGTTCTAGAGGCCCTGTGGTGAGG TCCTGC′3 (reverse). Modified PCR cDNA was digested using BstBI and XbaI enzymes and cloned in the pPICZ-HuMOR-cmyc-his-tag vector (Sarramegna et al., 2005) digested with the same enzymes leading to the creation of pPICZ-Hco-Pgp-13-cmyc-his-tag vector.
E. coli strain Top10F’ was used for the propagation of recombinant plasmids. E. coli transformants were selected on low salt LB plates pH 7.5 (0.5% w/v yeast extract, 1% w/v tryptone, 0.5% w/v NaCl, 1.5% w/v bacteriological agar) supplemented with 25 μg zeocin/ml. P. pastoris SMD1163 (his4, pep4, prB1) strain was used for protein expression. Transformants were selected on YPDS plates (1% w/v yeast extract, 2% w/v peptone, 2% w/v dextrose, 1 M sorbitol, and 1.5% w/v bacteriological agar) with 100 μg zeocin/ml. P. pastoris growth and induction were performed in BMGY medium (1% w/v yeast extract, 2% w/v peptone, 0.1 M phosphate buffer pH 7.5, 1% v/v glycerol) and BMMY medium (same as BMGY except that glycerol was replaced by 0.5% v/v methanol), respectively. For some experiments growth and recombinant protein expression were undertaken at the same time in BMMY medium. Cell cultures were conducted at 30 °C in shacking flasks.
2.7. Cell membrane preparation and western blot
P. pastoris and LLC-PK1 cells were harvested and ruptured during 30 min with glass beads, or by sonication, in buffer (Tris/HCl 10 mM, pH 7.5) supplemented with protease inhibitors, at 4 °C. The cell lysate was centrifuged at 1,000g for 15 min to remove particulate matter. The supernatant was then centrifuged at 100,000g for 30 min. Resulting pellets were stored at -80 °C in the same buffer. Membrane protein content was determined using the Bradford assay (Bio-Rad), using bovine serum albumin (BSA) as standard.
SDS-PAGE and transfer to nitrocellulose were performed as described (Gallagher, 2016). The primary anti-His tag antibody (Thermo Scientific) was diluted 1:1000 as well as the two primary antibodies designed against each epitope of Hco-Pgp-13. The secondary CF™770 anti-rabbit antibody (Biotium, Fremont, CA, USA) was used at a 1:10000 dilution. Detection was carried out using the Odyssey® CLx imaging system (LI-COR Biosciences, Lincoln, NE, USA).
2.8. ATPase activity measurements
The vanadate-sensitive ATPase activity of freshly prepared crude membranes from P. pastoris cells transformed by pPICZ-Hco-Pgp-13-cmyc-his-tag vector (Hco-Pgp-13: three membrane preparations) were compared to P. pastoris cells transformed by pPICZ-HuMOR-cmyc-his-tag vector (Sarramegna et al., 2005) (Hu-MOR: two membrane preparations) as negative controls and to untransfected P. pastoris cells (WT: three membrane preparations). The ATPase activity was measured at 37 °C by the endpoint inorganic phosphate (Pi) release assay (Sarkadi et al., 1992). Briefly, membrane preparations (200 μg/ml) were pre-incubated at 37 °C in ATPase assay buffer (50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM dithiothreitol, 0.1 mM EGTA, 10 mM sodium azide, 1 mM ouabain) in the presence or absence of 100 μM sodium orthovanadate and with increasing concentrations of either ACD or IVM. DMSO (final concentration was 1%) was used as solvent for the drugs and in the control measurements. The reaction was initiated by the addition of 5 mM ATP and stopped with 5% SDS solution after 5, 15 and 30 min of incubation. The amount of Pi released was determined at each time point in triplicate and the mean initial hydrolysis rate was calculated in nmol Pi/min/mg of total membrane protein (+/- SD). The vanadate sensitive activity values were estimated as the difference between the rate in the presence and absence of vanadate. For studying ACD-induced ATPase, in each of the different membrane preparations, data were normalized to 100% with respect to the vanadate-sensitive activity measured in the absence of added drug. For studying IVM modulation of ATPase activity data are presented as absolute values. In order to quantitatively analyze the interaction of ACD and IVM with Hco-Pgp-13, we assumed that these ligands have one specific site (or indepemdent sites) on the protein, and fitting was carried out using non-linear regression with GraphPad PRISM.
2.9. Construction of 3D models of Hco-Pgp-13 and in silico docking calculations
All Modeller and Autodock calculations were performed using the computing facilities of the CEA-DSV/GIPSI (cluster Gabriel) at Saclay, France and of INRA (Genotoul) in Toulouse, France. 3D models of Hco-Pgp-13 were built using Modeller 9v12 (Sali and Blundell, 1993, Webb and Sali, 2014) based on the crystal structure of C. elegans Pgp-1 (PDB: 4F4C, determined at a resolution of 3.4 Å), as a template (Jin et al., 2012). As the Cel-Pgp-1 sequence was lacking the following amino acids: M1-R3, A52-E54, K666-E715 and G1307-K1321, the full-length sequence of Hco-Pgp-13 was modeled without the corresponding aligned residues: M1-S3, E668-L725, and G1304-T1317. The pairwise alignment was deduced from the multiple alignment (Supplementary Figure S2) in order to improve the accuracy of the homology modeling alignment used as input for Modeller 9v12. Then, 100 models were generated in each Modeller run, and they were ranked according to their DOPE (Discrete Optimized Protein Energy) score and their molecular PDF value of the optimized objective function of Modeller. The best DOPE score model, n°4 (Hco-Pgp-13_04), and the best molecular PDF model, n°52 (Hco-Pgp-13_52), were submitted to various online servers to assess their protein structure quality (Supplementary Table S2). The QMEAN (Qualitative Model Energy Analysis) scoring function (Benkert et al., 2008, Benkert et al., 2009), the ProSA-web (Protein structure analysis) (Sippl, 1993, Wiederstein and Sippl, 2007) and the VADAR (Volume, Area, Dihedral Angle Reporter) (Willard et al., 2003) servers all indicated very close assessment for the two models according to different parameters, so that both of them were retained for docking calculations.
The in silico docking calculations for ACD and IVM on Hco-Pgp-13 were performed as previously described (David et al., 2016). The structure of ACD was extracted from DrugBank n° DB00970 and the structure of IVM was extracted from the Merck Index (https://www.rsc.org:merck-index). For both molecules, 10 minimum energy conformers were generated with Marvin Suite under the MMFF94 force field (https://www.chemaxon.com/products/marvin/marvinsketch/). After 3D-alignment and calculation of RMSD under PyMOL four representative conformers were chosen for starting the docking calculations. Molecular docking experiments were performed using AutoDock 4 (release 4.2.6) in the semi-flexible mode, with the Hco-Pgp-13_04 and Hco-Pgp-13_52 PDB structures kept rigid, and prepared with AutoDock Tools (Morris et al., 1998, Morris et al., 2009). The grid built by AutoGrid 4 included 95, 120, and 100 points in x, y, and z directions, with a grid spacing of 0.375 Å, to allow a good compromise between resolution of the explored volume and the size of the binding area (box dimensions 35.6 × 45.0 × 37.5 Å, centered in the inner cavity of Hco-Pgp-13 at the point x = 23 Å; y = 78 Å; z = -2 Å). For each ligand conformer, 100 runs were performed using the Lamarckian genetic algorithm. All the other parameters were set at the default value. The 100 generated poses were assigned a score calculated by AutoDock that can be considered as an estimated free energy of ligand binding (indicative of binding affinity). They were then clustered as a function of the closeness of their positions and conformations, with RMSD set at 2.0 Å, and finally ranked by their binding score (determined for the best pose in the cluster). For each lowest energy pose of selected clusters, the number and nature of interacting residues were analyzed within the protein. Among these, particular interest was given to residues belonging to the “hotspots for drug binding”. These are a collection of 62 residues, as displayed in Supplementary Table S3, coming from different experimental approaches that have been conducted for the purpose of determining the key residues responsible for multidrug recognition by mammalian Pgp (Hsa-ABCB1, Mmu-ABCB1a, Mmu-ABCB1b, Cgr-ABCB1) (Loo and Clarke, 2001, Loo and Clarke, 2002, Shilling et al., 2006, Loo et al., 2006a, Loo et al., 2006b, Aller et al., 2009, Bessadok et al., 2011, Li et al., 2013). All these residues are situated in the transmembrane part of the protein, and 14 of these 62 residues are common between at least two different approaches. Altogether, they provide a frame in the inner chamber that offers a set of anchor points for multi-specific recognition and binding, and eventual translocation, of various transport ligands. Multiple protein sequence alignments have been performed on Hco-Pgp-13, Cel-Pgp-1, human ABCB1, murine ABCB1a and B1b, and Chinese hamster ABCB1, using Muscle software (Edgar, 2004a), to identify the corresponding residues in Hco-Pgp-13.
2.10. Immunohistochemistry on larvae and adult H. contortus cryosections
The anti-Hco-Pgp-13 antibodies validated in Western-blot were used for immunohistofluorescence detection of Hco-Pgp-13 protein in L3 larvae and adult H. contortus. An anti-myosin antibody directed against C. elegans myosin heavy chain A was also used to localize muscles (product 5-6 of Developmental Studies Hybridoma Bank, University of Iowa, IA, USA). Fresh worms were fixed in 4% PFA in PBS at 4 °C for 16 h. They were then washed and incubated in 30% sucrose in PBS at 4 °C for 16 h. Whole worms were individually embedded in an optimal cutting temperature compound (OCT) (Thermo Fisher Scientific, Waltham, MA, USA), they were quickly frozen to -80 °C and stored. Cryosections were performed by slicing 20-30 μm thick transverse sections with a Thermo Shandon cryotome (Thermo Fisher Scientific) and slices were collected onto poly-L-lysine coated glass coverslips (Sigma, USA), and kept at -80 °C before further processing.
Sections were incubated in Antibody Diluent (AbD) (PBS, 0.2% gelatin fish skin, 0.1% sodium azide, 0.1% v/v Triton X-100) at 4 °C for 16 h, followed by incubation with the two primary antibodies: anti-myosin and anti-Hco-Pgp-13 with 1/100 and 1/50 dilutions, respectively, in AbD at 4 °C for 16 h. Five washes for 5 min with AbD were performed and the secondary fluorescent antibodies (Alexa Fluor 488-labelled fragment of goat anti-rabbit IgG and Alexa Fluor 635 goat anti -mouse IgG (Invitrogen, USA) were incubated at a 1/500 dilution at 4 °C for 16 h. Sections were washed three times for 5min with AbD and then PBS, mounted on slides using mounting medium (Sigma, Saint Louis, MO, USA) and observed under a fluorescent microscope. The most representative cross-sections were finally 3D analyzed under a confocal microscope (Leica SP8 DMI6000, Wetzlar, Germany) at excitation and emission wavelength of 488/520 nm, respectively for Alexa Fluor 488, and 635/650 nm, respectively, for AlexaFluor 635.
3. Results
3.1. The Hco-Pgp-13 corrected cDNA sequence encodes a protein matching the topology of an ABC transporter with high sequence similarity with Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14
RNA was extracted from adult male and female H. contortus, reverse transcribed into cDNA and amplified. Several primers (Supplementary Table S1) were designed along the predicted sequence of Hco-Pgp-13 (ftp://ftp.sanger.ac.uk/pub/pathogens/Haemonchus/contortus) (Laing et al., 2013). The full sequence obtained, named Hco-Pgp-13, corresponds to a 3954 base pairs (bp) coding cDNA from the ATG start codon to the TGA stop codon (Supplementary Figure S1) and is representative of the transcript RNA present in the parasitic worms (GenBank No. KX844966). Compared to the gene sequence previously published (Laing et al., 2013), the alignment data revealed a deletion of 30 nucleotides in the amplified cDNA sequence, which strictly matched a 30-nucleotide repeat present in the Hco-Pgp-13 sequence predicted in the published genome (Supplementary Figure S1). We deduced that this was due to a misalignment of contigs in the genomic sequencing. In addition, 90 single nucleotide polymorphisms (SNPs) were found over the full length amplified cDNA, which represents 2.3% of the nucleotide sequence (Supplementary Figure S1).
The deduced amino acid sequence of Hco-Pgp-13 contains 1317 residues, and corresponds to an expected molecular weight of 145.9 kDa. It contains eight N-glycosylation motifs, without putative O-glycosylation sites or signal peptide (Fig. 1). It is predicted to possess four structural domains with two hydrophobic transmembrane domains (TMD) and two cytoplasmic domains. The predicted motifs in the nucleotide binding domains (NBD) correspond to ABC transporter family signature motifs (Hewitt and Lehner, 2003) LSGGQKQRI (residues 557–565) in NBD1, and LSGGQKQRI (residues 1215–1223) in NBD2. Aromatic residues (Y427 and Y1085) were found located 25 amino acids upstream of each Walker A motif. These conserved motifs, involved in the hydrolysis of ATP, are consistent with a functional, primary active transporter.
A multiple sequence alignment was performed with all Hco-Pgps, all Cel-Pgps and two mammalian Pgps: Hsa-Pgp and Mmu-ABCB1a, after exclusion of the highly conserved NBDs (Supplementary Figure S2). A phylogenetic tree (Fig. 2) shows that with and without NBDs, (Laing et al., 2013), Hco-Pgp-13 displays a very high degree of homology to Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14, which thus all three appear to be orthologs of Hco-Pgp-13.
3.2. Tertiary structure of Hco-Pgp-13 was generated by homology modeling to Cel-Pgp-1
Since Cel-Pgp-1 is the only crystallographic structure of a nematode Pgp (Protein Data Bank: 4F4C), the homologies of Cel-Pgp-1 TMDs sequences with the TMDs sequences of all other aligned Pgps (Supplementary Figure S2) were calculated using BlastP (Table 1). As expected, Cel-Pgp-1 presented the highest homology for TMDs to Hco-Pgp-1, with 63% identity and 79% similarity of residues, followed by Cel-Pgp-9 and Hco-Pgp-9. Interestingly, N-terminal regions, in the multiple alignment, showed a sequence which extends to 70-90 amino acids for Hco-Pgp-10, Hco-Pgp-13, Cel-Pgp-1, Cel-Pgp-10, Cel-Pgp-11, Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14, against 30-50 amino acids for the nineteen other Pgp sequences aligned, including Hco-Pgp-1 (Table 1, bold, and Supplementary Figure S2). In the crystal structure of Cel-Pgp-1, a transmembrane hairpin (TMa-b, Supplementary Figure S3) was found in the N-terminal region (Jin et al., 2012). Among the Pgps harboring this long N-terminal region (bold, Table 1), Hco-Pgp-13 TMDs showed the highest degree of homology to Cel-Pgp-1 TMDs, with 33% identity and 54% similarity. In contrast, the only other Pgp sequence of H. contortus harboring a long N-terminal region, Hco-Pgp-10, only showed 22% identity and 42% similarity to Cel-Pgp-1 TMDs.
The Cel-Pgp-1 4F4C crystal structure was used as a template for building 3D homology models of Hco-Pgp-13, according to the pairwise alignment shown in Supplementary Figure S3. Two models, Hco-Pgp-13_04 and Hco-Pgp-13_52, showed the highest accuracy and very similar scores for quality evaluation (Supplementary Table S2). The open inward-facing conformations of these two high quality models (Supplementary Figure S4) were substantially superimposed. Closer inspection of TMDs of both models showed transmembrane (TM) helices aligned with Cel-Pgp-1 alpha helices, including the small hairpin formed by the N-terminal regions, with a slight shift of their backbones. The TM1 helix and the extracellular loop 1 (ECL1) were found to be shorter in Hco-Pgp-13 than in Cel-Pgp-1 (Supplementary Figure S4B).
When comparing the two Hco-Pgp-13 models, a difference was found in the middle of TM11, where the alpha helix is discontinued only in Hco-Pgp-13_04. At the core of the TMDs, the orientation of the side chains of residues varied between the two models from being almost superimposed (e.g., L366) to pointing in opposite directions (e.g., L1026) (Supplementary Figure S4C).
Interestingly, amino acids of these two Hco-Pgp-13 models, which aligned with those experimentally found to interact with substrates in mammalian Pgps (called “hotspot residues”) (Supplementary Table S3), were mostly found (80%) to point towards the inner chamber formed by the 12 TM helices, thus in an orientation favorable for interaction with potential substrates.
3.3. Hco-Pgp-13 shows in silico high affinity binding sites for ACD and IVM
In order to obtain insights into the functioning of Hco-Pgp-13, we studied, using in silico docking on the two structural models, the ability of the protein to interact with two key ligands: ACD, a well-established substrate of mammalian Pgp and Cel-Pgp-1, and IVM, which is the most important anthelmintic used to control parasitic nematodes.
For ACD, the two lowest energy clusters obtained from the docking calculations showed very good binding energies; -16.0 kcal/mol and -14.4 kcal/mol for the Hco-Pgp-13_04 and Hco-Pgp-13_52 models, respectively (Table 2); such energy scores are considered to indicate very high affinity for ligand-protein interaction (Morris et al., 1998, Morris et al., 2009). The binding location of ACD was very close in the two models, occupying the inner chamber of Hco-Pgp-13 from its cytoplasmic opening to its inner core (Fig. 3A and B). These two models of ACD binding showed a similar number of interacting residues: 20 with Hco-Pgp-13_04 model (including 11 hotspot residues) and 19 with Hco-Pgp-13_52 (including 9 hotspot residues). Twelve predicted interacting residues, among which 7 hotspot residues, were common between the two models, with some similarly oriented (e.g., E21, L365, T369) but most of them pointing towards different orientations (e.g. Q108, M916, M995, M1032, N1033) (Fig. 3C and D and Table 2). These differences would explain the different lowest energy positions for ACD in the two models, with different H-bonds formed. For example, Q108, which formed an H-bond with Hco-Pgp-13_04 model, but not with Hco-Pgp-13_52, had a very different orientation in the two models. In contrast, T369 formed an H-bond with Hco-Pgp-13_52 but not with Hco-Pgp-13_04, despite similar orientations. Two H-bonds were formed in both cases, and one of them, formed with N1033, was common between the two models (Fig. 3C and D and Table 2). All three H-bond forming residues were hotspot residues, underlining their importance in substrate binding across species. The role of the small hairpin formed by TMa-b was also significant, as three residues from TMb, i.e. E21, K25 and L29, participated in the stability of ACD on this site in both models (Fig. 3C and D and Table 2). These results indicate a very high affinity of ACD for Hco-Pgp-13 with a very close binding site in the two models, located in the cytoplasmic opening of the inner chamber, and thus not much dependent on the orientation of partially flexible residues composing the TMDs.
Table 2.
For IVM, the docking calculations, performed on each model of Hco-Pgp-13, showed close lowest energy clusters, -11.2 kcal/mol and -12.8 kcal/mol for the Hco-Pgp-13_04 model and the Hco-Pgp-13_52 model, respectively, indicating high affinity binding in both cases (Table 2). The binding location of IVM on the Hco-Pgp-13_04 model was close to the cytoplasmic opening of the chamber (Fig. 3A), whereas the binding site of IVM on Hco-Pgp-13_52 was in the deepest part of the inner chamber of the protein (Fig. 3B). These binding positions interacted with 14 residues on model Hco-Pgp-13_04, and 21 residues on model Hco-Pgp-13_52, including 4 hotspots and formed 2 H-bonds on Hco-Pgp-13_04, and 14 hotspots and no H-bonds on Hco-Pgp-13_52 (Fig. 3E and F and Table 2). Thus the binding locations found on the two models were different, with only 5 common residues and with different H-bonds formed: S19 and E21 on Hco-Pgp-13_04, and V1029 and M1032 on Hco-Pgp-13_52 (Fig. 3E and F and Table 2). The binding site of IVM on Hco-Pgp-13 thus appears dependent on the orientation of amino-acids lining the binding chamber. For the Hco-Pgp-13_04 model, it mostly superimposed with the binding site of ACD; the two molecules sharing 9 common interacting residues, including 3 hotspots residues, whereas on Hco-Pgp-13_52, the binding sites of IVM and ACD only superimposed each other at their extremities; nonetheless sharing 6 interacting residues, including 4 hotspots residues.
From this analysis, it can be predicted that both ACD and IVM specifically interact with Hco-Pgp-13 with high affinity at partially overlapping locations within the inner chamber formed by the TMDs. Consequently, these data predict competitive binding of these two ligands on Hco-Pgp-13.
3.4. Hco-Pgp-13 is functionally expressed in transfected P. pastoris cells
The ability of Hco-Pgp-13 to interact with ACD and IVM was also studied by analyzing modulation of its ATPase activity. We transfected P. pastoris cells with the pPICZ-Hco-Pgp-13-cmyc-his-tag vector. The relative expression of Hco-Pgp-13 in the transfected cells was checked by Western blot using an antibody anti-His tag and two specific antibodies. To generate specific antibodies, two antigenic peptides were designed to be specific to Hco-Pgp-13, compared to other H. contortus Pgps. When proteins of crude membrane were analyzed by Western-blot, only the 130-kDa protein, otherwise detected with an anti-His tag antibody (Supplementary Figure S5A) reacted with each antibody, showing that the two epitopes were antigenic (Supplementary Figure S5B and C) and confirming that Hco-Pgp-13 was well expressed in the membrane of the transfected P. pastoris. The anti-Hco-Pgp-13 antibodies did not give any signal with untransfected mammalian LLCPK1 cells or untransfected P. pastoris cells, while the Hco-Pgp-13 transfected cells gave a strong signal to the anti-Hco-Pgp-13 antibodies (Supplementary Figure S5A, B, C). To confirm that the anti-Hco-Pgp-13 antibodies were specific, we checked for any cross reaction with Hco-Pgp-2 and found no cross reactivity (Supplementary Figure S5D, E).
We found that P. pastoris membranes from cells expressing Hco-Pgp-13 displayed a higher vanadate-sensitive ATPase activity (150 ± 18 nmol/min/mg) compared to P. pastoris cells transfected with pPICZ-HuMOR-cmyc-his-tag vector, used as control (95 ± 5 nmol/min/mg), showing that Hco-Pgp-13 displays a basal ATPase activity (55 ± 23 nmol/min/mg) in the absence of any exogenous compound.
3.5. Hco-Pgp-13 ATPase activity is modulated by ACD and IVM
ACD stimulated vanadate-sensitive ATPase activity in Hco-Pgp-13 expressing P. pastoris membranes, in a concentration dependent manner with a biphasic profile (Fig. 4A). An activity enhancement of about 1.6-fold and a half-activating concentration around 0.6–1 μM (EC50) were observed. In contrast, IVM specifically inhibited the basal ATPase activity of Hco-Pgp-13 with a concentration-dependent response curve (Fig. 4B). The concentration giving 50% of the maximal inhibition (IC50) was around 0.5–0.7 μM. In addition, we observed on Hco-Pgp-13 containing membranes, that the ACD-dependent ATPase stimulation was completely inhibited in the presence of 5 μM of IVM (Fig. 4A).
In contrast, in membranes from P. pastoris control cells expressing HuMOR, as well as in the membranes from non-transfected P. pastoris, the activity was neither activated by ACD nor inhibited by IVM up to 10 μM (Fig. 4A and B). The slight inhibiting effect observed at 10-20 μM is likely attributable to non-specific membrane perturbing effect, which could also explain the small activity decrease observed at 20 μM ACD on Hco-Pgp-13 containing membranes (Fig. 4A and B). Globally, these ATPase modulations strongly indicate that ACD and IVM bind specifically to Hco-Pgp-13 with sub-micromolar apparent affinity.
3.6. Hco-Pgp-13 is expressed in H. contortus digestive, neuronal and epithelial tissues
Given that Hco-Pgp-13 appears likely to be a functional transporter that interacts with IVM and hence possibly plays a role in modulating IVM levels in nematode tissues, it was of interest to determine the expression sites of Hco-Pgp-13. The two anti-Hco-Pgp-13 antibodies were used as a mixture in immunofluorescence assays on transverse cryosections of larvae and adult parasites. In larvae, the Hco-Pgp-13 expression was found in the seam cell between muscle quadrants and more generally in the hypodermis around muscles, including dense bodies between myosin filaments (grey and white arrows, Fig. 5A, panels I and II). Significant staining was also observed at epithelial cells membranes of developing internal organs, corresponding to the gonad or intestine, which could not be readily distinguished at this stage of development (yellow arrow, Fig. 5A, panel II).
In the adult H. contortus, Hco-Pgp-13 signal was also found in seam cells-excretory cells, between muscle quadrants and in the surrounding hypodermis (grey and white arrows, Fig. 5B, panels I-IV), as well as at the surface of the male gonad (yellow arrow, Fig. 5B, panel I). In adults, some staining also appeared in the pharynx procorpus at the level of pharyngeal nerve cords that contain cell bodies of epithelial cells, longitudinal extensions of neurons and pharyngeal gland cell processes (purple arrows, Fig. 5B panel II). The staining observed in the metacorpus and terminal bulb also matches the extensions or cell bodies of pharyngeal neurons and gland cells (purple arrows, Fig. 5B, panels III and IV). Additional staining appeared in the head sections between the pharynx and seam cells (blue arrows, Fig. 5B panels III and IV), and within the structure localized at the level of seam cells in other sections (blue arrows, Fig. 5B, panel II). This corresponds to the location of amphidial neurons. Indeed, their dendrites run parallel to the pharynx from the nerve ring to the tip of the head, where seam cells end, and correspond to the amphids. Overall, this broad protein localization matches several organs of the digestive, neuronal, excretory and epithelial systems, suggesting an important physiological role for Hco-Pgp-13.
4. Discussion
There is evidence Pgp efflux pumps play a role in ML resistance in nematodes. Since there is limited structural and functional information on ABC transporters in parasitic nematodes, examining Pgps from H. contortus, is important to understand their role. We focused on Hco-Pgp-13 since its ortholog in C. elegans is expressed in the nematode amphids, the strategic organs controlling chemotaxis, and for which a defect is associated with IVM resistance (Urdaneta-Marquez et al., 2014, Menez et al., 2016). Our overall objective was to characterize Hco-Pgp-13 and determine whether it could interact with drugs in order to predict its capacity to transport anthelmintics. Our data strongly support that Hco-Pgp-13 specifically interacts with IVM with high affinity, and may thus actively transport IVM and protect sensitive nematode tissues.
4.1. Topology and 3D structural models of Hco-Pgp-13
We first corrected the predicted Hco-pgp-13 cDNA from the H. contortus genome (Laing et al., 2013) by identifying a misalignment of contigs due to a 30-nucleotide repeat in the previously published genomic sequence, absent in the full-length amplified cDNA. In addition, 90 single nucleotide polymorphisms (SNPs) were found in the amplified cDNA, similar to the 2.3% frequency of SNPs reported in different H. contortus populations. Based on the corrected sequence (GenBank No. KX844966), the full-length cDNA allowed prediction of a protein containing 1137 amino acids (MW 146 kDa), with typical domain arrangement of full-size ABC proteins, including 2 TMDs, and 2 NBDs containing the ABC transporter family consensus motifs, consistent with a primary active transporter. Hco-Pgp-13 shared close similarities with Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14, suggesting these proteins are orthologs between the two nematode species, possibly sharing some functional homologies.
Since the TMDs of Hco-Pgp-13 also share high sequence homology with the TMDs of Cel-Pgp-1 (54% similarity by BlastP), we generated 3D structures of Hco-Pgp-13 by homology modeling using the Cel-Pgp-1 crystal structure 4F4C (Jin et al., 2012), as template. Two model proteins Hco-Pgp-13_04 and Hco-Pgp-13_52 were selected according to their similarly high quality scores for several parameters (Table S2). They were both organized into two halves containing each six TM helices, but they presented an unusual supplementary transmembrane hairpin TMa-b at the N-terminus. For both models, 80% of hotspots residues, involved in drug binding in mammalian Pgps (Table S3), were detected and pointed towards the inner chamber lined by the TMDs. Nineteen percent of them were conserved, in terms of their nature, slightly below the 26% of hotspots residues conserved in Cel-Pgp-1 (David et al., 2016) as compared with mammalian Pgps. These data suggest that the overall protein topology of the inner chamber of Hco-Pgp-13 is consistent with a multispecific drug recognition site compatible with a multidrug transport function. However, only a small number of ABC proteins are endowed with a multidrug recognition capacity, and this raises the question of ligands interacting with Hco-Pgp-13.
4.2. High-affinity interaction of Hco-Pgp-13 with ACD and IVM
To study the ability of two toxins, ACD and IVM, to bind to Hco-Pgp-13, we characterized the putative binding sites in silico, by docking the two drugs on the two homology models described above. Allowing AutoDock 4 to “challenge” two different protein conformations with a semi-flexible docking strategy gave it the opportunity to explore a larger conformational space of the protein, which could simulate, to some extent, a flexible docking calculation strategy. The two conformations may reflect a preexisting equilibrium of two pools of proteins which may be stabilized upon ligand binding as the result of the movement of interacting residues or various membrane domains (Pike, 2004, Andre et al., 2008). ACD was chosen because this drug has been reported to strongly stimulate the ATPase activity of Cel-Pgp-1 (Jin et al., 2012) and to interact with the Cel-Pgp-1 binding pocket in silico, having the highest affinity among all tested ligands (David et al., 2016). We found that ACD and IVM both bound with high affinity in the inner chamber, revealing they are ligands of Hco-Pgp-13. The large ligand ACD (1255 Da) bound in the chamber from the cytoplasmic opening to the transmembrane inner core of the protein, whatever the protein model, while IVM (875 Da) presented a dual binding site, depending on the conformation of the protein. One of the binding sites of IVM substantially overlapped that of ACD in one protein model (_04), whereas it was deeper in the inner chamber and only partially overlapped the binding site of ACD in the other protein conformation (_52). The data revealed that the affinity of the binding site for a given ligand may depend on the conformation of the protein. Each ligand is expected to stabilize the lower energy conformation state of the formed complex. ACD seems to bind preferentially to the Hco-Pgp-13_04 conformation, whereas IVM has a higher affinity for the Hco-Pgp-13_52 conformation. In other words, the two built structural models are not “alternative” models, but are complementary conformations describing a preexisting dynamic transconformation equilibrium contributing to the specific affinity recognition of different ligands. The docking approach also provided important insights into drug interacting residues of the Hco-Pgp-13 binding pocket. Several residues formed H-bonds, among them, E21, L365, M1032 are common for ACD and IVM binding. In addition, several amino acids also aligned to hotspot residues on mammalian Pgp, suggesting that the inner chamber of Hco-Pgp-13 could form a binding domain competent for recognizing transport substrates of unrelated chemicals.
The ability to bind ACD and IVM was confirmed in vitro by measuring modulation of ATPase activity in cell membranes expressing Hco-Pgp-13. ACD specifically stimulated the basal Hco-Pgp-13 ATPase activity. The ACD half-activating concentration for Hco-Pgp-13 stimulation (EC50 = 0.6–1 μM) was higher than that for Cel-Pgp-1 (EC50 ≈ 0.05 μM) (Jin et al., 2012); however, the experimental conditions differed between the two sets of measurements. The in silico docking of ACD on Cel-Pgp-1 showed that it interacts with a comparable binding energy as with Hco-Pgp-13, at a similar site located at the cytosolic opening of the inner chamber (David et al. to be submitted). Since ATP hydrolysis is required to drive active translocation across cell membranes, our data indicate that ACD is transported by Hco-Pgp-13 similarly to Cel-Pgp-1. Interestingly, in the absence of any added drug, a higher ATPase activity in the membranes of yeast expressing Hco-Pgp-13, as compared to that of the control membranes, suggests that Hco-Pgp-13 can transport some substrates present in the membranes.
IVM inhibited the basal Hco-Pgp-13 ATPase activity in a concentration dependent-manner with an apparent half-maximal inhibitory concentration of 0.5–0.7 μM, which suggests that it can specifically bind to Hco-Pgp-13. In addition, the total inhibition of the ACD-stimulated ATPase activity by 5 μM IVM is consistent with binding to the same site as that inhibiting the basal activity, which was half-saturated at ≈ 0.6 μM. The consistency between the two effects of IVM strongly supports that it binds to a specific site on Hco-Pgp-13 with a sub-micromolar affinity. It is noteworthy that it has also been reported that the interaction of IVM with mammalian Pgp induces an inhibition of its basal ATPase activity (Lespine et al., 2007). This inhibition was explained as the consequence of a slower translocation of IVM than that of endogenous substrates, including cholesterol (Garrigues et al., 2002).
In silico docking calculations indicated a lower affinity for IVM than ACD for its specific binding site (binding energy of -12,8 vs -16,0 kcal/mol, respectively). In contrast, in vitro experiments showed similar apparent affinities, in the 0.5 to 1 μM range. If we consider that Hco-Pgp-13 behaves like mammalian Pgp and, in its open inward-facing conformation, binds its hydrophobic substrates from within the membrane (Sharom, 2008, Eckford and Sharom, 2009), the in vitro measured affinity of an amphiphilic/hydrophobic ligand will be a combination of its membrane partition coefficient and the “theoretical affinity” with its specific binding site. Since IVM is much more hydrophobic than ACD, it will be more concentrated within the membrane, hence the in silico data can be quantitatively reconciled by considering that the higher membrane partition coefficient of IVM compensates for its lower theoretical affinity. In silico calculations also showed that IVM was docked, for the more stable conformation, in the deepest part of the inner chamber of the protein, which was in agreement with the previously determined in silico docking of IVM on Cel-Pgp-1 (David et al., 2016). Finally the in silico data predict that IVM should inhibit ACD-induced ATPase stimulation, due to the partial overlap of their drug binding sites, and this was observed in vitro.
4.3. Tissue immunolocalization of Hco-Pgp-13
It was of interest to determine in which tissues of H. contortus Hco-Pgp-13 is expressed. Hco-Pgp-13 was found in the digestive apparatus, which can be an entry route for xenobiotics; in the seam cells lining the excretory canals, involved in xenobiotic elimination; and in head neurons, possibly the amphids, which may play a role in the access of ML to the targets responsible for lethal anthelmintic effects on nematodes. Since shortening of amphidial dentrites is associated with resistance to IVM in H. contortus and in C. elegans (Freeman et al., 2003, Urdaneta-Marquez et al., 2014, Menez et al., 2016), the staining of adult head neurons matching the amphids suggests a link for Hco-Pgp-13 involvement in IVM resistance. The pharyngeal structures were also stained, and may correspond with the neurons innervating the pharynx. Since a major effect of ML on nematodes is paralysis of the pharyngeal muscles, Hco-Pgp-13 expression in pharyngeal neurons might protect worms from IVM effects. The expression of Hco-Pgp-13 in the epithelial cells of the larvae and adult gonad resembled previous finding of Hco-Pgp-9.1 expression in the uterus (Godoy et al., 2016), and an involvement in reducing toxic compounds reaching embryos, as was shown in C. elegans (Brinke et al., 2013) and mammalian placental tissue (Nakamura et al., 1997, Kolwankar et al., 2005).
The Hco-Pgp-13 expression matches the global transcript localization of all of its closest ortholog genes in C. elegans with Cel-Pgp-12 expressed in the excretory cell, Cel-Pgp-13 in the posterior intestine and amphids of adults, Cel-Pgp-14 in the anterior region and first bulb of the pharynx in the adults and larvae, and Cel-Pgp-15 in the adult head and tail neurons, and in the embryo (Zhao et al., 2004). Interestingly, the three genes Cel-Pgp-12, Cel-Pgp-13, Cel-Pgp-14, together with the pseudogene Cel-Pgp-15, form a cluster of tandemly duplicated genes on chromosome X of C. elegans (Zhao et al., 2004). Since, H. contortus lacks the Pgp-12 and Pgp-14 proteins, the broad localization observed here for Hco-Pgp-13 may cover all the functions ensured in C. elegans by its three ortholog Pgps.
This study represents the first structural and functional analysis of a parasitic nematode Pgp, describing its molecular interaction with two important drugs, ACD and IVM. This provides critical information on the protective function of Hco-Pgp-13 against toxicity of IVM and other drugs. Its location, mainly in strategic tissues of H. contortus, underlines the importance of this transporter and its possible role in anthelmintic resistance.
Acknowledgements
The authors thank Lea Lasvaux and Melanie Gentil for their help in the ATPase activity measurements and Western-blot experiments, Thierry Gauthier for providing his expertise and access to confocal microscope. We also thank Fabien Jourdan and Clément Frainay for technical support with bioinformatics experiments and the Genotoul Bioinformatics hardware infrastructure that was used for computing. We also acknowledge the staff of the computing facility of the Biology division of CEA/DRF/GIPSI at Saclay for help and access to the national cluster Gabriel. This work was supported by the Natural Sciences and Engineering Research Council of Canada (grant No. RGPIN/2777-2012), the FRQNT Centre for Host-Parasite Interactions, Quebec, and EMIDA ERA-NET project CARES n 11-EMID-003-02.
Footnotes
Supplementary data related to this article can be found at https://doi.org/10.1016/j.ijpddr.2018.02.001.
Contributor Information
Roger K. Prichard, Email: roger.prichard@mcgill.ca.
Anne Lespine, Email: anne.lespine@inra.fr.
Appendix A. Supplementary data
The following are the supplementary data related to this article:
References
- Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323:1718–1722. doi: 10.1126/science.1168750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Andre A., Gaibelet G., Le Guyader L., Welby M., Lopez A., Lebrun C. Membrane partitioning of various delta-opioid receptor forms before and after agonist activations: the effect of cholesterol. Biochim. Biophys. Acta. 2008;1778:1483–1492. doi: 10.1016/j.bbamem.2008.03.017. [DOI] [PubMed] [Google Scholar]
- Ardelli B.F., Prichard R.K. Inhibition of P-glycoprotein enhances sensitivity of Caenorhabditis elegans to ivermectin. Vet. Parasitol. 2013;191:264–275. doi: 10.1016/j.vetpar.2012.09.021. [DOI] [PubMed] [Google Scholar]
- Bartley D.J., McAllister H., Bartley Y., Dupuy J., Ménez C., Alvinerie M., Lespine A. P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcincta and Haemonchus contortus. Parasitology. 2009;136:1081–1088. doi: 10.1017/S0031182009990345. [DOI] [PubMed] [Google Scholar]
- Benkert P., Tosatto S.C.E., Schomburg D. QMEAN: a comprehensive scoring function for model quality assessment. Protein. Struct. Funct. Bioinf. 2008;71:261–277. doi: 10.1002/prot.21715. [DOI] [PubMed] [Google Scholar]
- Benkert P., Künzli M., Schwede T. QMEAN server for protein model quality estimation. Nucleic Acids Res. 2009;37(Suppl. 2):510–514. doi: 10.1093/nar/gkp322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bessadok A., Garcia E., Jacquet H., Martin S., Garrigues A., Loiseau N., Vivaudou M. Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins. J. Biol. Chem. 2011;286:3552–3569. doi: 10.1074/jbc.M110.155200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Blaxter M., Liu L. Nematode spliced leaders-ubiquity, evolution and utility. Int. J. Parasitol. 1996;26:1025–1033. [PubMed] [Google Scholar]
- Brinke M., Heininger P., Traunspurger W. Effects of a bioassay-derived ivermectin lowest observed effect concentration on life-cycle traits of the nematode Caenorhabditis elegans. Ecotoxicology. 2013;22:148–155. doi: 10.1007/s10646-012-1011-3. [DOI] [PubMed] [Google Scholar]
- Campbell W.C. Ivermectin: a reflection on simplicity (nobel lecture) Angew. Chem. Int. Ed. Engl. 2016;55:10184–10189. doi: 10.1002/anie.201601492. [DOI] [PubMed] [Google Scholar]
- Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 1988;16:10881–10890. doi: 10.1093/nar/16.22.10881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- David M.A., Orlowski S., Prichard R.K., Hashem S., Andre F., Lespine A. In silico analysis of the binding of anthelmintics to Caenorhabditis elegans P-glycoprotein 1. Int. J. Parasitol. Drugs Drug Res. 2016;6:299–313. doi: 10.1016/j.ijpddr.2016.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eckford P.D.W., Sharom F. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 2009;109:2989–3011. doi: 10.1021/cr9000226. [DOI] [PubMed] [Google Scholar]
- Edgar R.C. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinf. 2004;5:113. doi: 10.1186/1471-2105-5-113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792–1797. doi: 10.1093/nar/gkh340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Freeman A.S., Nghiem C., Li J., Ashton F.T., Guerrero J., Shoop W.L., Schad G.A. Amphidial structure of ivermectin-resistant and susceptible laboratory and field strains of Haemonchus contortus. Vet. Parasitol. 2003;110:217–226. doi: 10.1016/s0304-4017(02)00321-7. [DOI] [PubMed] [Google Scholar]
- Gallagher S.R. One-dimensional SDS gel electrophoresis of proteins. Curr. Protoc. Immunol. 2016:1–44. doi: 10.1002/0471142735.im0804s75. Chapter 10: Unit 10.1. [DOI] [PubMed] [Google Scholar]
- Garrigues A., Loiseau N., Delaforge M., Ferté J., Garrigos M., André F., Orlowski S. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol. Pharmacol. 2002;62:288–1298. doi: 10.1124/mol.62.6.1288. [DOI] [PubMed] [Google Scholar]
- Godoy P., Lian J., Beech R.N., Prichard R.K. Haemonchus contortus P-glycoprotein-2: in situ localisation and characterisation of macrocyclic lactone transport. Int. J. Parasitol. 2015;45:85–93. doi: 10.1016/j.ijpara.2014.09.008. [DOI] [PubMed] [Google Scholar]
- Godoy P., Che H., Beech R.N., Prichard R.K. Characterization of Haemonchus contortus P-glycoprotein-16 and its interaction with the macrocyclic lactone anthelmintics. Mol. Biochem. Parasitol. 2015;204:11–15. doi: 10.1016/j.molbiopara.2015.12.001. [DOI] [PubMed] [Google Scholar]
- Godoy P., Che H., Beech R.N., Prichard R.K. Characterisation of P-glycoprotein-9.1 in Haemonchus contortus. Parasit. Vectors. 2016;9:52. doi: 10.1186/s13071-016-1317-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hewitt E.W., Lehner P.J. The ABC-transporter signature motif is required for peptide translocation but not peptide binding by TAP. Eur. J. Immunol. 2003;33:422–427. doi: 10.1002/immu.200310016. [DOI] [PubMed] [Google Scholar]
- James C.E., Davey M.W. Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans. Int. J. Parasitol. 2009;39:213–220. doi: 10.1016/j.ijpara.2008.06.009. [DOI] [PubMed] [Google Scholar]
- Janssen I.J., Krucken J., Demeler J., von Samson-Himmelstjerna G. Caenorhabditis elegans: modest increase of susceptibility to ivermectin in individual P-glycoprotein loss-of-function strains. Exp. Parasitol. 2013;134:171–177. doi: 10.1016/j.exppara.2013.03.005. [DOI] [PubMed] [Google Scholar]
- Janssen I.J., Krücken J., Demeler J., Basiaga M., Kornaś S., von Samson-Himmelstjerna G. Genetic variants and increased expression of Parascaris equorum P-glycoprotein-11 in populations with decreased ivermectin susceptibility. PLoS One. 2013;8 doi: 10.1371/journal.pone.0061635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Janssen I.J., Krucken J., Demeler J., von Samson-Himmelstjerna G. Transgenically expressed Parascaris P-glycoprotein-11 can modulate ivermectin susceptibility in Caenorhabditis elegans. Int. J. Parasitol. Drugs Drug Resist. 2015;5:44–47. doi: 10.1016/j.ijpddr.2015.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jin M.S., Oldham M.L., Zhang J., Chen Q. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature. 2012;490:566–569. doi: 10.1038/nature11448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones P.M., George A.M. Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling. Int. J. Parasitol. 2005;35:555–566. doi: 10.1016/j.ijpara.2005.01.012. [DOI] [PubMed] [Google Scholar]
- Kaplan R.M., Vidyashankar A.N. An inconvenient truth: global worming and anthelmintic resistance. Vet. Parasitol. 2012;186:70–78. doi: 10.1016/j.vetpar.2011.11.048. [DOI] [PubMed] [Google Scholar]
- Kaschny M., Demeler J., Janssen I.J.I., Kuzmina T.A., Besognet B., Kanellos T., Kerboeuf T., von Samson-Himmelstjerna G., Krücken J. Macrocyclic lactones differ in interaction with recombinant P-glycoprotein 9 of the parasitic nematode Cylicocylus elongatus and ketoconazole in a yeast growth assay. PLoS Pathog. 2015;11 doi: 10.1371/journal.ppat.1004781. e1004781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koenderink J.B., Kavishe R.A., Rijpma F.G., Russel S.R. The ABCs of multidrug resistance in malaria. Trends Parasitol. 2010;26:440–446. doi: 10.1016/j.pt.2010.05.002. [DOI] [PubMed] [Google Scholar]
- Kolwankar D., Glover D.D., Ware T.S., Tracy J.A. Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab. Dispos. 2005;33:524–529. doi: 10.1124/dmd.104.002261. [DOI] [PubMed] [Google Scholar]
- Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents. 2003;22:188–199. doi: 10.1016/s0924-8579(03)00203-6. [DOI] [PubMed] [Google Scholar]
- Laing R., Kikuchi T., Martinelli A., Tsai I.J., Beech R.N., Redman E., Holroyd N., Bartley D.J., Beasley H., Britton C., Curran D., Devaney E., Gilabert A., Hunt M., Jackson F., Johnston S.L., Kryukov I., Li K., Morrison A.A., Reid A.J., Sargison N., Saunders G.I., Wasmuth J.D., Wolstenholme A., Berriman M., Gilleard J.S., Cotton J.A. The genome and transcriptome of Haemonchus contortus, a key model parasite for drug and vaccine discovery. Genome Biol. 2013;14 doi: 10.1186/gb-2013-14-8-r88. R88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lespine A., Martin S., Dupuy J., Roulet A., Pineau T., Orlowski S., Alvinerie M. Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur. J. Pharm. Sci. 2007;30:84–94. doi: 10.1016/j.ejps.2006.10.004. [DOI] [PubMed] [Google Scholar]
- Lespine A., Menez C., Bourguinat C., Prichard R.K. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int. J. Parasitol. Drugs Drug Resist. 2012;2:58–75. doi: 10.1016/j.ijpddr.2011.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li J., Jaimes K.F., Aller S.G. Refined structures of mouse P-glycoprotein. Protein. Sci. 2013;23:34–46. doi: 10.1002/pro.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Loo T.W., Clarke D.M. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J. Biol. Chem. 2001;276:14972–14979. doi: 10.1074/jbc.M100407200. [DOI] [PubMed] [Google Scholar]
- Loo T.W., Clarke D.M. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. 2002;277:44332–44338. doi: 10.1074/jbc.M208433200. [DOI] [PubMed] [Google Scholar]
- Loo T.W., Bartlett M.C., Clarke D.M. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J. 2006;396:537–545. doi: 10.1042/BJ20060012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Loo T.W., Bartlett M.C., Clarke D.M. Transmembrane segment 7 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J. 2006;399:351–359. doi: 10.1042/BJ20060715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mani T., Bourguinat C., Keller K., Ashraf S., Blagburn B., Prichard R.K. Interaction of macrocyclic lactones with a Dirofilaria immitis P-glycoprotein. Int. J. Parasitol. 2016;46:631–640. doi: 10.1016/j.ijpara.2016.04.004. [DOI] [PubMed] [Google Scholar]
- Menez C., Alberich M., Kansoh D., Blanchard A., Lespine A. Acquired tolerance to ivermectin and moxidectin after drug selection pressure in the nematode Caenorhabditis elegans. Antimicrob. Agents Chemother. 2016;60:4809–4819. doi: 10.1128/AAC.00713-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998;19:1639–1662. [Google Scholar]
- Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785–2791. doi: 10.1002/jcc.21256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakamura Y., Ikeda S., Furukawa T., Sumizawa T., Tani A., Akiyama S., Nagata Y. Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. 1997;235:849–853. doi: 10.1006/bbrc.1997.6855. [DOI] [PubMed] [Google Scholar]
- Omasits U., Ahrens C.H., Muller S., Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics. 2014;30:884–886. doi: 10.1093/bioinformatics/btt607. [DOI] [PubMed] [Google Scholar]
- Pike L.J. Lipid rafts: heterogeneity on the high seas. Biochem. J. 2004;378:281–292. doi: 10.1042/BJ20031672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pouliot J.F., L'Heureux F., Liu Z., Prichard R.K., Georges E. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem. Pharmacol. 1997;53:17–25. doi: 10.1016/s0006-2952(96)00656-9. [DOI] [PubMed] [Google Scholar]
- Ranjan S., Wang G.T., Hirschlein C., Simkins K.L. Selection for resistance to macrocyclic lactones by Haemonchus contortus in sheep. Vet. Parasitol. 2002;103:109–117. doi: 10.1016/s0304-4017(01)00551-9. [DOI] [PubMed] [Google Scholar]
- Roulet A., Puel O., Gesta S., Lepage J.F., Drag M., Soll M., Alvinerie M., Pineau T. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 2003;460:85–91. doi: 10.1016/s0014-2999(02)02955-2. [DOI] [PubMed] [Google Scholar]
- Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993;234:779–815. doi: 10.1006/jmbi.1993.1626. [DOI] [PubMed] [Google Scholar]
- Sarkadi B., Price E.M., Boucher R.C., Germann U.A., Scarborough G.A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 1992;267:4854–4858. [PubMed] [Google Scholar]
- Sarramegna V., Muller I., Mousseau G., Froment C., Monsarrat B., Milon A., Talmont F. Solubilization, purification, and mass spectrometry analysis of the human mu-opioid receptor expressed in Pichia pastoris. Protein Expr. Purif. 2005;43:85–93. doi: 10.1016/j.pep.2005.05.007. [DOI] [PubMed] [Google Scholar]
- Schinkel A.H., Smit J.J.M., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502. doi: 10.1016/0092-8674(94)90212-7. [DOI] [PubMed] [Google Scholar]
- Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–127. doi: 10.2217/14622416.9.1.105. [DOI] [PubMed] [Google Scholar]
- Shilling R.A., Venter H., Velamakanni S., Bapna A., Woebking B., Shahi S., van Veen H.W. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol. Sci. 2006;27:195–203. doi: 10.1016/j.tips.2006.02.008. [DOI] [PubMed] [Google Scholar]
- Sippl M.J. Recognition of errors in three-dimensional structures of proteins. Proteins. 1993;17:355–362. doi: 10.1002/prot.340170404. [DOI] [PubMed] [Google Scholar]
- Urdaneta-Marquez L., Bae S.H., Janukavicius P., Beech R., Dent J., Prichard R. A dyf-7 haplotype causes sensory neuron defects and is associated with macrocyclic lactone resistance worldwide in the nematode parasite Haemonchus contortus. Int. J. Parasitol. 2014;44:1063–1071. doi: 10.1016/j.ijpara.2014.08.005. [DOI] [PubMed] [Google Scholar]
- Webb B., Sali A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinformatics. 2014;47(5):1–32. doi: 10.1002/0471250953.bi0506s47. 6. [DOI] [PubMed] [Google Scholar]
- Wiederstein M., Sippl M.J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35:W407–W410. doi: 10.1093/nar/gkm290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Willard L., Ranjan A., Zhang H., Monzavi H., Boyko R.F., Sykes B.D., Wishart D.S. VADAR: a web server for quantitative evaluation of protein structure quality. Nucleic Acids Res. 2003;31:3316–3319. doi: 10.1093/nar/gkg565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ōmura S.A. Splendid gift from the earth: the origins and impact of the avermectins (nobel lecture) Angew. Chem. Int. Ed. 2016;55:10190–10209. doi: 10.1002/anie.201602164. [DOI] [PubMed] [Google Scholar]
- Zhao Z., Sheps J.A., Ling V., Fang L.L., Baillie D.L. Expression analysis of ABC transporters reveals differential functions of tandemly duplicated genes in Caenorhabditis elegans. J. Mol. Biol. 2004;344:409–417. doi: 10.1016/j.jmb.2004.09.052. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.